Compare XLO & RDI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XLO | RDI |
|---|---|---|
| Founded | 2016 | 1937 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Movies/Entertainment |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 56.9M | 49.0M |
| IPO Year | 2021 | 1994 |
| Metric | XLO | RDI |
|---|---|---|
| Price | $9.04 | $2.01 |
| Analyst Decision | Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $28.00 | N/A |
| AVG Volume (30 Days) | 9.2K | ★ 85.0K |
| Earning Date | 05-14-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 60.76 |
| EPS | N/A | ★ N/A |
| Revenue | $43,766,000.00 | ★ $202,988,000.00 |
| Revenue This Year | N/A | $16.25 |
| Revenue Next Year | $168.77 | $4.04 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 589.88 | N/A |
| 52 Week Low | $0.46 | $0.94 |
| 52 Week High | $9.90 | $2.41 |
| Indicator | XLO | RDI |
|---|---|---|
| Relative Strength Index (RSI) | 48.64 | 50.19 |
| Support Level | $8.63 | $0.99 |
| Resistance Level | $9.15 | $2.41 |
| Average True Range (ATR) | 0.24 | 0.13 |
| MACD | 0.00 | -0.04 |
| Stochastic Oscillator | 21.83 | 14.70 |
Xilio Therapeutics Inc is a clinical-stage biotechnology company focused on discovering and developing masked immuno-oncology (I-O) therapies to improve outcomes for people living with cancer. Leveraging its clinically validated masking technology and capabilities, the company develops I-O therapies designed to selectively activate within the tumor microenvironment to achieve durable efficacy without the severe side effects associated with systemically active I-O agents. Its integrated biology and protein engineering approach enables the design and development of potent masked biologics that are activated by tumor-specific proteases.
Reading International Inc is a diversified company, engaged in the development, ownership, and operation of multiplex cinemas and retail and commercial real estate in the United States, Australia, and New Zealand. It operates through two segments: the Cinema segment includes Reading Cinemas, Angelika Film Center, Consolidated Theatres, and City Cinemas; the Real Estate segment includes real estate development and the rental or licensing of retail, commercial and live theater assets.